Related Experiment Videos
Biobusiness in the pharmaceutical industry
1Dr. Karl Thomae GmbH, Bioengineering Techniques, Biberach an der Riss, Fed. Rep. of Germany.
Arzneimittel-Forschung
|September 1, 1987
Summary
New biotechnology, using genetic engineering, produces complex pharmaceutical compounds like human insulin and interferons. These novel biopharmaceuticals often reach the market faster than traditional drugs, with ROI depending on market competition and clinical efficacy proof.
Area of Science:
- Biotechnology
- Pharmaceutical Science
- Genetic Engineering
Background:
- Conventional biotechnology relies on screening natural strains for pharmaceutical compound synthesis.
- New biotechnology utilizes genetic engineering to program organisms for producing specific human proteins and glycoproteins.
Purpose of the Study:
- To highlight the increasing importance and applications of new biotechnology in pharmaceutical production.
- To categorize and discuss novel biopharmaceutical products developed through genetic engineering.
Main Methods:
- Genetic engineering of known organisms to produce specific human proteins and glycoproteins.
- Development of recombinant products for substitution therapy and novel therapeutic applications.
Main Results:
- New biotechnology yields complex products like human insulin, growth hormone, interferons, and vaccines.
- Several recombinant products, including human insulin and interferons, have successfully reached the market.
- Biopharmaceuticals often achieve market approval faster than conventional chemical drugs due to faster clinical efficacy demonstration.
Conclusions:
- New biotechnology offers safer and novel alternatives to existing pharmaceuticals.
- Market success and return on investment for biopharmaceuticals are influenced by market competition and the ease of demonstrating clinical efficacy.